Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant.

Perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) are compounds that do not occur in nature but have been widely used since World War II and persist indefinitely in the environment. They are present in the serum of Americans with median levels of 4 ng/mL and 21 ng/mL, respectively. PFOA has been positively associated with cholesterol in several studies of workers. A cross-sectional study of lipids and PFOA and PFOS was conducted among 46,294 community residents aged 18 years or above, who drank water contaminated with PFOA from a chemical plant in West Virginia. The mean levels of serum PFOA and PFOS in 2005-2006 were 80 ng/mL (median, 27 ng/mL) and 22 ng/mL (median, 20 ng/mL), respectively. All lipid outcomes except high density lipoprotein cholesterol showed significant increasing trends by increasing decile of either compound; high density lipoprotein cholesterol showed no association. The predicted increase in cholesterol from lowest to highest decile for either compound was 11-12 mg/dL. The odds ratios for high cholesterol (>/=240 mg/dL), by increasing quartile of PFOA, were 1.00, 1.21 (95% confidence interval (CI): 1.12, 1.31), 1.33 (95% CI: 1.23, 1.43), and 1.40 (95% CI: 1.29, 1.51) and were similar for PFOS quartiles. Because these data are cross-sectional, causal inference is limited. Nonetheless, the associations between these compounds and lipids raise concerns, given their common presence in the general population.

[1]  F. Gilliland,et al.  Mortality among employees of a perfluorooctanoic acid production plant. , 1993, Journal of occupational medicine. : official publication of the Industrial Medical Association.

[2]  Mark R Cullen,et al.  Longitudinal Study of Serum Lipids and Liver Enzymes in Workers With Occupational Exposure to Ammonium Perfluorooctanoate , 2007, Journal of occupational and environmental medicine.

[3]  J. Mandel,et al.  PLASMA CHOLECYSTOKININ AND HEPATIC ENZYMES, CHOLESTEROL AND LIPOPROTEINS IN AMMONIUM PERFLUOROOCTANOATE PRODUCTION WORKERS , 2000, Drug and chemical toxicology.

[4]  Geary W Olsen,et al.  Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers , 2007, International archives of occupational and environmental health.

[5]  Bogdan Szostek,et al.  Quantitative determination of perfluorooctanoic acid in serum and plasma by liquid chromatography tandem mass spectrometry. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[6]  Anders G. Olsson,et al.  Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment , 2008, Circulation.

[7]  John W Green,et al.  Cross-Sectional Study of Lipids and Liver Enzymes Related to a Serum Biomarker of Exposure (ammonium perfluorooctanoate or APFO) as Part of a General Health Survey in a Cohort of Occupationally Exposed Workers , 2007, Journal of occupational and environmental medicine.

[8]  M. A. Mohd,et al.  Perfluorooctanesulfonate and related fluorochemicals in human blood from several countries. , 2004, Environmental science & technology.

[9]  T. Fletcher,et al.  Predictors of PFOA Levels in a Community Surrounding a Chemical Plant , 2009, Environmental health perspectives.

[10]  John W. Froehlich,et al.  Half-Life of Serum Elimination of Perfluorooctanesulfonate,Perfluorohexanesulfonate, and Perfluorooctanoate in Retired Fluorochemical Production Workers , 2007, Environmental health perspectives.

[11]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[12]  Eric Langlois,et al.  An interlaboratory study of perfluorinated alkyl compound levels in human plasma. , 2008, Environmental research.

[13]  Jørn Olsen,et al.  Perfluorinated Chemicals and Fetal Growth: A Study within the Danish National Birth Cohort , 2007, Environmental health perspectives.

[14]  M. Fernández,et al.  The LDL to HDL Cholesterol Ratio as a Valuable Tool to Evaluate Coronary Heart Disease Risk , 2008, Journal of the American College of Nutrition.

[15]  L. Shaw,et al.  Community Exposure to Perfluorooctanoate: Relationships Between Serum Levels and Certain Health Parameters , 2006, Journal of occupational and environmental medicine.

[16]  R. Luebke,et al.  Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha. , 2009, Critical reviews in toxicology.

[17]  Rolf U. Halden,et al.  Cord Serum Concentrations of Perfluorooctane Sulfonate (PFOS) and Perfluorooctanoate (PFOA) in Relation to Weight and Size at Birth , 2007, Environmental health perspectives.

[18]  Roger G Perkins,et al.  The Toxicology of Perfluorooctanoate , 2004, Critical reviews in toxicology.

[19]  Gerald L Kennedy,et al.  Comparative responses of rats and mice exposed to linear/branched, linear, or branched ammonium perfluorooctanoate (APFO). , 2006, Toxicology.

[20]  J. Mandel,et al.  Serum perfluorooctane sulfonate and hepatic and lipid clinical chemistry tests in fluorochemical production employees. , 1999, Journal of occupational and environmental medicine.

[21]  J. M. Symons,et al.  Retrospective cohort mortality study of workers in a polymer production plant including a reference population of regional workers. , 2008, Annals of epidemiology.

[22]  A. Calafat,et al.  Polyfluoroalkyl Chemicals in the U.S. Population: Data from the National Health and Nutrition Examination Survey (NHANES) 2003–2004 and Comparisons with NHANES 1999–2000 , 2007, Environmental health perspectives.

[23]  X Yu,et al.  J.Chromatogr., B: Anal. Technol. Biomed. Life Sci. , 2004 .

[24]  D. Consonni,et al.  Thirty Years of Medical Surveillance in Perfluooctanoic Acid Production Workers , 2009, Journal of occupational and environmental medicine.

[25]  R J Havel,et al.  Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. , 1998, The American journal of cardiology.